Antimicrobial Sensitivity Patterns Among Pediatric Cystic Fibrosis Patients: Implications for Effective Treatment Strategies
Keywords:
Cystic Fibrosis, Pediatric Patients, AntibiogramAbstract
Background: Patients with cystic fibrosis (CF) who have recurrent bacterial lung infections eventually develop respiratory incompetency, which increases morbidity and death. It's important to treat these patients promptly to achieve positive results.Objective: To explore the Antimicrobial sensitivity pattern of pediatric cystic fibrosis patients.Methodology: This observational study was conducted from April 2022 to September 2022 at the Department of Paediatric Medicine, Qazi Hussain Ahmad Medical Complex, Nowshera, Pakistan. Regarding the health status of pediatric CF patients, extensive evaluations were conducted as part of the diagnostic evaluation and data-gathering procedure for this study. Physical examination and laboratory testing like culture and sensitivity were performed. To evaluate the antimicrobial sensitivity pattern Kirby Bauer modified disc diffusion method was used. Version 26 of the SPSS software was used to carry out the statistical analysis. The p-value level of 0.05 has been defined as a measure of statistical significance.Results: A total of 84 children with CF symptoms were included in the research. Of these patients, there were 28 females (33.3%) and 56 boys (66.6%). Among the respiratory samples taken from pediatric CF patients, the most prevalent isolated bacteria was Pseudomonas aeruginosa (36%) followed by Klebsiella pneumonia (22.9%). Among all bacterial strains, Ciprofloxacin and Levofloxacin had the highest levels of antimicrobial sensitivity, whereas Amoxicillin, Erythromycin, and Rifampicin showed significant resistance.Conclusion: Our study concludes that P. aeruginosa was the most prevalent isolated bacteria followed by Klebsiella pneumonia in patients with cystic fibrosis. The most effective antimicrobial agents in our study were ciprofloxacin and levofloxacin.References
Elborn JS. Cystic fibrosis. Lancet.2016; 388(10059):2519-31.
Goetz D, Ren CL. Review of cystic fibrosis. Pediatr Ann. 2019;48:e154-61.
Wine JJ, Hansson GC, König P. Progress in understanding mucus abnormalities in cystic fibrosis airways. J Cyst Fibrosis.2018;17:S35-9.
Collawn JF, Matalon S. CFTR and lung homeostasis. Am J Physiol Lung Cell Mol Physiol. 2014;307:L917-23.
Cardines R, Giufre M, Pompilio A. Haemophilus infuenzae in children with cystic fibrosis : antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int J Med Microbiol. 2012;302:45-52.
Wong JK, Ranganathan SC, Hart E. State of the art Staphylococcus aureus in early cystic fibrosis lung disease. Pediatr Pulmonol.2013;1159:1151-9.
Parkins MD, Floto RA. Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J Cyst Fibrosis. 2015;14:293-304.
Malhotra S, Hayes D, Wozniak DJ. Cystic fibrosis and. Clin. Microbiol Rev. 2019;32:138-218.
Cuthbertson L, Walker AW, Oliver AE. Lung function and microbiota diversity in cystic fibrosis. Micro Biome. 2020;8:1-13.
Garcia-Clemente M, de la Rosa D, Máiz L. Impact of pseudomonas aeruginosa infection on patients with chronic inflammatory airway diseases. J Clin Med.2020;9:3800.
Smyth AR, Smith SJ, Rowbotham NJ. Infection prevention and control in cystic fibrosis: one size fts all the argument against. Pediatric Respir Rev.2020;36:94-6.
Farahm and F, Khalili M, Shahbaznejad L. Clinical presentation of cystic fibrosis at the time of diagnosis: a multicenter study in a region without newborn screening. Turk J Gastroenterol.2013; 24(6):541-6.
Kabra SK, Kabra M, Lodha R. Clinical profile and frequency of delta f508 mutation in Indian children with cystic fibrosis. Indian Pediatr. 2003;40(7):612-9.
Aziz DA, Billoo AG, Qureshi A, Khalid M, Kirmani S. Clinical and laboratory profile of children with Cystic Fibrosis: Experience of a tertiary care center in Pakistan. Pak J Med Sci. 2017;33:554.
Bhinder MA, Sadia H, Mahmood N, Qasim M, Hussain Z, Rashid MM, et al. Consanguinity: A blessing or menace at population level? Ann Hum Genet. 2019;83:214-219.
Nobandegani NM, Mahmoudi S, Pourakbari B. Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern. Microb Pathog.2016;100:201-4.
Pressler T, Bohmova C, Conway S, Dumcius S, Hjelte L, Høiby N, et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros. 2011;10 2:S75-8.
Van den Bossche, S, De Broe, E. Coenye, T, Van Braeckel, E, Crabbé, A. The cystic fibrosis lung microenvironment alters antibiotic activity: Causes and effects. Eur. Respir. Rev. 2021;30:210055.
Valenza G, Tappe D, Turnwald D; Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008;7:123-7.
Chang RY, Das T, Manos J, Kutter E, Morales S, Chan HK. Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients. AAPS J. 2019;21:1-8.
Che Hamzah AM, Yeo CC, Puah SM, Chua KH, Chew CH. Staphylococcus aureus infections in Malaysia: A review of antimicrobial resistance and characteristics of the clinical isolates, 1990–2017. Antibiotics. 2019;8:128.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
